Septic shock after allogeneic hematopoietic stem-cell transplantation: outcomes and prognostic factors in a multicenter ICU cohort.

IF 9.8 1区 医学 Q1 CRITICAL CARE MEDICINE
Chest Pub Date : 2026-08-28 DOI:10.1016/j.chest.2026.06.075
Marielle Subileau, Dara Chean, Thibault Dupont, Emmanuel Canet, Anne-Sophie Moreau, Muriel Picard, Djamel Mokart, Laura Platon, Julien Mayaux, Florent Wallet, Nahema Issa, Jean-Herlé Raphalen, Frédéric Pène, Anne Renault, Delphine Arnales, Caroline Van De Wyngaert, Hélène Kemp, Aliénor Xhaard, Naike Bigé, Michaël Darmon, Elie Azoulay, Antoine Lafarge
{"title":"Septic shock after allogeneic hematopoietic stem-cell transplantation: outcomes and prognostic factors in a multicenter ICU cohort.","authors":"Marielle Subileau, Dara Chean, Thibault Dupont, Emmanuel Canet, Anne-Sophie Moreau, Muriel Picard, Djamel Mokart, Laura Platon, Julien Mayaux, Florent Wallet, Nahema Issa, Jean-Herlé Raphalen, Frédéric Pène, Anne Renault, Delphine Arnales, Caroline Van De Wyngaert, Hélène Kemp, Aliénor Xhaard, Naike Bigé, Michaël Darmon, Elie Azoulay, Antoine Lafarge","doi":"10.1016/j.chest.2026.06.075","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Septic shock is a major cause of intensive care unit (ICU) admission among allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, yet data on its epidemiology and prognosis remain limited.</p><p><strong>Research question: </strong>We aimed to describe outcomes, identify independent prognostic factors, and explore associations that may inform early management.</p><p><strong>Study design and methods: </strong>We performed a multicenter retrospective cohort study including allo-HSCT recipients admitted to the ICU with septic shock between 2015 and 2020.</p><p><strong>Results: </strong>Among 1,164 allo-HSCT recipients hospitalized in ICU, 38% (n=444) were admitted for septic shock. The median SOFA score was 8 (IQR, 6-11). Microbiological documentation was obtained in 62% (n=261), including fungal pathogens in 17% (n=74). The respiratory tract was the most common infection source (43%, n=180). Invasive mechanical ventilation and renal replacement therapy were required in 64% (n=284) and 32% (n=143), respectively. Mortality at 90 days and 3 years was 63% (n=280) and 81% (n=350). In the extended Cox model, fungal documentation (HR 1.78 [95% CI, 1.19-2.67], p=0.005), SOFA score (HR 1.07 [95% CI, 1.02-1.13], p=0.007), and neutropenia (HR 3.94 [95% CI, 1.18-13.1], p=0.026) were independently associated with 90-day survival. In a 48-hour landmark analysis, early aminoglycoside use was associated with higher 90-day survival (HR 0.46 [95% CI, 0.33-0.64], p<0.001). However, time-varying analyses indicated a non-constant association over time. Age ≥ 56 years (HR 1.36, [95% CI, 0.99-1.87]), GvHD type, and early bacterial documentation (HR 0.90, [95% CI, 0.64-1.26]) were not associated with 90-day survival.</p><p><strong>Interpretation: </strong>Septic shock after allo-HSCT carries a high mortality (63% at 90 days), largely driven by host-related factors and initial illness severity. The association between aminoglycoside use and outcome is complex, does not support a straightforward causal interpretation, and warrants further prospective evaluation.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8000,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2026.06.075","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Septic shock is a major cause of intensive care unit (ICU) admission among allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, yet data on its epidemiology and prognosis remain limited.

Research question: We aimed to describe outcomes, identify independent prognostic factors, and explore associations that may inform early management.

Study design and methods: We performed a multicenter retrospective cohort study including allo-HSCT recipients admitted to the ICU with septic shock between 2015 and 2020.

Results: Among 1,164 allo-HSCT recipients hospitalized in ICU, 38% (n=444) were admitted for septic shock. The median SOFA score was 8 (IQR, 6-11). Microbiological documentation was obtained in 62% (n=261), including fungal pathogens in 17% (n=74). The respiratory tract was the most common infection source (43%, n=180). Invasive mechanical ventilation and renal replacement therapy were required in 64% (n=284) and 32% (n=143), respectively. Mortality at 90 days and 3 years was 63% (n=280) and 81% (n=350). In the extended Cox model, fungal documentation (HR 1.78 [95% CI, 1.19-2.67], p=0.005), SOFA score (HR 1.07 [95% CI, 1.02-1.13], p=0.007), and neutropenia (HR 3.94 [95% CI, 1.18-13.1], p=0.026) were independently associated with 90-day survival. In a 48-hour landmark analysis, early aminoglycoside use was associated with higher 90-day survival (HR 0.46 [95% CI, 0.33-0.64], p<0.001). However, time-varying analyses indicated a non-constant association over time. Age ≥ 56 years (HR 1.36, [95% CI, 0.99-1.87]), GvHD type, and early bacterial documentation (HR 0.90, [95% CI, 0.64-1.26]) were not associated with 90-day survival.

Interpretation: Septic shock after allo-HSCT carries a high mortality (63% at 90 days), largely driven by host-related factors and initial illness severity. The association between aminoglycoside use and outcome is complex, does not support a straightforward causal interpretation, and warrants further prospective evaluation.

异基因造血干细胞移植后感染性休克:多中心ICU队列的结果和预后因素
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chest
Chest 医学-呼吸系统
CiteScore
13.70
自引率
3.10%
发文量
3369
审稿时长
15 days
期刊介绍: At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书